SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : LSBC -- Large Scale Biology Corp.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Findit who wrote (117)5/21/2003 9:28:48 AM
From: tuck   of 144
 
>>VACAVILLE, Calif.--(BUSINESS WIRE)--May 21, 2003--Large Scale Biology Corporation (Nasdaq:LSBC - News) will evaluate field production this quarter for its proprietary plant-produced human alpha-Galactosidase A as a potential treatment for Fabry disease. A lysomal storage disorder, Fabry disease is characterized by the accumulation of lipids (fats) in vital organs such as the kidney, often resulting in death during the fourth or fifth decade of life. Market estimates for the enzyme replacement therapeutic exceed $1 billion annually.

In January, the FDA granted LSBC orphan drug designation for the product which the Company plans to develop in a commercial partnership. LSBC President and CEO Kevin J. Ryan told a meeting of Company scientists that LSBC will proceed aggressively with its program to produce what it envisions as an ultimately more effective second-generation drug for Fabry patients.

The alpha-Galactosidase program is part of LSBC corporate strategy to produce specialty biologics for revenue while demonstrating the robust properties of its proprietary GENEWARE® technology for producing therapeutic drugs in plants. LSBC's technology provides an efficient method for producing biopharmaceuticals by using non-genetically modified organisms (non-GMO), non-food plants for production purposes. The commercial scale-up program for alpha-Galactosidase A is the responsibility of LSBC's biomanufacturing division in Owensboro, Kentucky. <<

snip

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News